A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer

(2010) Chris Twelves et al.   Clinical Breast Cancer

Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine

(2010) Javier Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells

(2010) Jan-Shiang Taur et al.   XENOBIOTICA

Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability

(2009) Jennifer A. Smith et al.   BIOCHEMISTRY

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety and biomarker results from Japanese patients phase II studies

(2009) M Toi et al.   BRITISH JOURNAL OF CANCER

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

(2009) S. Goel et al.   CLINICAL CANCER RESEARCH

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

(2009) A. R. Tan et al.   CLINICAL CANCER RESEARCH

Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy

(2009) P. H. O'Donnell et al.   CLINICAL CANCER RESEARCH

Phase II Study of Gemcitabine Monotherapy as a Salvage Treatment for Japanese Metastatic Breast Cancer Patients after Anthracycline and Taxane Treatment

(2009) Y. Suzuki et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2009) Linda T. Vahdat et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane

(2009) Alvaro Moreno-Aspitia et al.   MAYO CLINIC PROCEEDINGS

MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome

(2009) M Cizmarikova et al.   PHARMACOGENOMICS JOURNAL

Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes

(2008) Takanori Ishida et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

(2008) T. Okouneva et al.   MOLECULAR CANCER THERAPEUTICS